CGM App & Alert Interface Patent Landscape 2026
Dexcom commands a dominant share of CGM app and alert interface patenting, holding more than four times the patent records of its nearest rival, Abbott Diabetes Care. The field is in a Growth stage on a multi-year basis, with recent-window filings running 28% above the prior period, though annual volume has eased from its 2022 peak.
Dexcom leads a highly concentrated field with a widening tier gap
Dexcom holds the top position with 117 patent records, nearly four-and-a-quarter times the count of the second-ranked Abbott Diabetes Care at 28. The top five filers—Dexcom, Abbott Diabetes Care, University of Virginia. Patent Foundation, Tandem Diabetes Care, and Medtronic MiniMed—account for 72% of the hundred largest filers’ combined total, signaling a tightly concentrated competitive structure.
The tier gap between first and second place is substantial and does not close quickly down the ranking. The University of Virginia. Patent Foundation at 18 patent records and Tandem Diabetes Care at 15 occupy a distinct second tier, while Medtronic MiniMed at 9 and smaller entrants from 8 down to 2 constitute a fragmented third tier.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Dexcom Inc | 117 | |
| 2 | Abbott Diabetes Care Inc | 28 | |
| 3 | University of Virginia Patent Foundation | 18 | |
| 4 | Tandem Diabetes Care Inc | 15 | |
| 5 | Medtronic MiniMed Inc | 9 | |
| 6 | Nudge BG Inc | 8 | |
| 7 | Animas Corporation | 7 | |
| 8 | Cambridge Enterprise Ltd | 6 | |
| 9 | Allez Health Inc | 5 | |
| 10 | LifeScan IP Holdings LLC | 5 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Insulet Corporation | 5 | |
| 12 | Ascensia Diabetes Care Holdings AG | 3 | |
| 13 | Roche Diabetes Care Inc | 3 | |
| 14 | Budiman Erwin S | 2 | |
| 15 | Cision US Inc | 2 | |
| 16 | Indian Institute of Technology Madras | 2 | |
| 17 | Hayter Gary A | 2 | |
| 18 | Roche Diabetes Care GmbH | 2 | |
| 19 | Wilinska Malgorzata E | 2 | |
| 20 | Taub Marc B | 2 |
Dexcom’s position implies deep control over core smartphone-integration and alert-logic approaches, as reflected in its technology emphasis across healthcare informatics, diagnostic sensing, and digital data processing. Challengers concentrating on closed-loop insulin delivery interfaces and AI-assisted alerting retain room to differentiate without directly contesting Dexcom’s densest claim clusters.
The most recent 18–24 months of filings are under-counted due to publication lag; apparent low volume in 2024–2026 should not be read as a slowdown. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Multi-year growth with a 2022 peak and a broadening technology mix
Two signals define the structural picture: a filing curve that rose to a 2022 peak and has since eased (with recent years further suppressed by publication lag), and a technology composition dominated by healthcare informatics and diagnostic sensing but with meaningful adjacent branches emerging.
Annual filing trend
Filings climbed from 23 in 2017, dipped in 2018, recovered through 2019–2021, and peaked at 32 in 2022. The count fell to 30 in 2023 and drops sharply to 11 in 2024 and 10 in 2025—figures that reflect publication lag rather than a real decline. On a multi-year basis the field grew 28% in the recent window versus the prior period.
↗ Hover for values · click a bar to ask EurekaTechnology composition
Healthcare informatics (G16H) and diagnostic sensing (A61B) dominate the branch mix, reflecting the core CGM data-management and sensor-interface functions. Electric digital data processing (G06F) and devices for body fluids (A61M) form a substantial secondary layer, while wireless networks (H04W), AI models (G06N), and display control (G09G) represent smaller but present adjacent branches.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
System, method and computer readable medium for co…
A system or method for compressing continuous glucose monitor (CGM) data for a subject and/or a technician, clinician, or for use with an interventional device. The system or method configures the CGM data to allow the subject, technician, clinician, or interventional device to take a physical action in response to receiving a transmission to improve the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Systems and methods for leveraging smartphone feat… | 257 |
| 2 | Systems and methods for leveraging smartphone feat… | 247 |
| 3 | Methods for reducing false hypoglycemia alarm occu… | 214 |
| 4 | Systems and methods for leveraging smartphone feat… | 201 |
| 5 | Systems and methods for consumer-generated media r… | 182 |
| 6 | Systems and methods for patient monitoring using a… | 172 |
| 7 | Method and system for closed-loop control of an ar… | 161 |
| 8 | Continuous glucose monitor communication with mult… | 138 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
The combination of high concentration, multi-year growth, and specific collaboration ties shapes both the risk profile and the opportunity surface for new entrants and incumbents alike.
Growth stage, easing from 2022 peak
The field carries a Growth lifecycle label: recent three-year filings sit well above the prior three-year window, producing 28% net growth. Annual volume peaked in 2022 at 32 records and has since eased, but publication lag means 2024–2026 data is materially undercounted. Investors should treat the field as still expanding, not plateauing.
Growth · 28% recent windowExtreme first-mover concentration; second tier is accessible
The top five filers hold 72% of the hundred largest filers’ combined total, with Dexcom alone at 117 patent records. The gap between the leader and the nearest challenger is large enough that a new entrant competing on identical claim terrain faces high freedom-to-operate risk. The second and third tiers—ranging from 28 down to 2 patent records—are more accessible for differentiated approaches such as AI-based alerting or display-optimization.
High concentrationSparse co-filing; Abbott–Cambridge is the active pair
Abbott Diabetes Care and Cambridge Enterprise have co-filed on 4 patent records, making them the most active collaboration pair in this corpus. Dexcom and the University of Padova have one co-filed record. The low overall collaboration count suggests the field is prosecuted primarily through internal portfolios rather than consortium arrangements, leaving academic-industry partnerships as a relatively open structural option.
Low co-filing densityUS-centric filing; EPO and PCT provide secondary reach
The United States is the dominant filing jurisdiction with 109 patent records, reflecting where the leading assignees are headquartered and where the consumer CGM market is most developed. Europe (EPO) at 38 and Australia at 24 form a secondary tier, with PCT at 23 providing international coverage optionality. China and India each carry only 5 records, indicating limited current defensive filing in high-growth emerging markets.
US-dominant, EPO secondaryGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Abbott Diabetes Care Inc | Cambridge Enterprise Ltd | 4 |
| Dexcom Inc | University of Padova | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Dexcom and Abbott anchor the field; challengers are entering fresh
Dexcom’s lead in healthcare informatics, sensing, and digital data processing is reinforced by volume that no single challenger can match in the near term. Abbott Diabetes Care and the University of Virginia. Patent Foundation are the most credible second-tier players, each with recent filing momentum categorized as new entrants in the current period.
Dexcom Inc
Dexcom holds 117 patent records, the single largest position in this corpus by a wide margin. Its technology emphasis spans healthcare informatics (G16H, 90 records), diagnostic sensing (A61B, 81 records), and digital data processing (G06F, 41 records), covering the full stack from sensor data management to app-level UI. Recent-period momentum shows a ▼ –16% trend versus the prior window, suggesting a measured pace rather than aggressive acceleration.
patent records: 117Abbott Diabetes Care Inc
Abbott Diabetes Care holds 28 patent records and is classified as a new entrant in the most recent filing window, indicating renewed or accelerated activity after a quiet prior period. Its technology focus mirrors Dexcom’s core stack—healthcare informatics (G16H, 28 records), therapeutic management informatics (G16H20, 27 records), and diagnostic sensing (A61B, 23 records)—positioning it as a direct competitor in the alert logic and data-management layers.
patent records: 28| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Dexcom Inc | 26 | ▼ -16% |
| Abbott Diabetes Care Inc | 1 | ▲ new entrant |
| University of Virginia Patent Foundation | 8 | ▲ new entrant |
| Tandem Diabetes Care Inc | 6 | ▲ new entrant |
| Medtronic MiniMed Inc | 5 | ▲ new entrant |
| Nudge BG Inc | 4 | ▲ new entrant |
| Insulet Corporation | 4 | ▲ new entrant |
| Allez Health Inc | 5 | ▲ new entrant |
Under-served branches in wireless, AI alerting, and display control
Five IPC branches carry low share relative to the dominant classes, each with plausible technical relevance to next-generation CGM alert interfaces. The sparsest—wireless networks, AI models, and display control circuits—represent areas where coverage is thin enough to allow differentiated filing.
G06N · AI-based alert models
With only 11 patent records and a 2% share, AI-model computing (G06N) is notably sparse given the relevance of machine-learning approaches to hypoglycemia prediction and false-alarm reduction—one of the most-cited problem statements in this corpus. Medtronic MiniMed is the only top-tier applicant with visible G06N focus (5 records), leaving room for entrants with ML-native alerting architectures. A realistic entry path is predictive threshold calibration or personalized alert suppression using on-device inference.
Search this in Eureka →G09G · Display control for CGM interfaces
Display control circuits (G09G) carry 17 patent records and a 3% share, which is low given the centrality of wearable and smartwatch display formats to CGM user experience. No top-five applicant shows a primary focus here, suggesting the branch is underclaimed relative to its commercial importance. An entry path exists through novel low-power or always-on display rendering methods specific to continuous glucose readout and configurable alert visualizations.
Search this in Eureka →How leaders differ in technology route emphasis
Route coverage across the main technology branches in the current evidence set.
| Player | G16H 40 · Healthcare informatics | A61B 5 · Diagnosis & surgery | G16H 20 · Healthcare informatics | A61M 5 · Devices for body fluids | G16H 50 · Healthcare informatics |
|---|---|---|---|---|---|
| Dexcom Inc | Strong · 90 | Strong · 81 | Moderate · 32 | Emerging · 12 | Moderate · 28 |
| Abbott Diabetes Care Inc | Strong · 28 | Strong · 23 | Strong · 27 | Strong · 19 | Strong · 18 |
| University of Virginia Patent Foundation | Strong · 18 | Strong · 12 | Strong · 13 | Moderate · 8 | Moderate · 9 |
| Tandem Diabetes Care Inc | Strong · 15 | Moderate · 5 | Strong · 14 | Strong · 12 | Moderate · 4 |
| Animas Corporation | Strong · 7 | Strong · 5 | Strong · 7 | Strong · 6 | Absent |
| Nudge BG Inc | Strong · 8 | Absent | Strong · 8 | Strong · 8 | Absent |
| Medtronic MiniMed Inc | Strong · 5 | Strong · 8 | Absent | Absent | Strong · 5 |
Frequently asked questions
The corpus contains 174 patent families in scope. Dexcom alone accounts for 117 patent records in the applicant ranking, reflecting its outsized position relative to all other filers.
Dexcom Inc is the clear leader with 117 patent records—roughly four times the count of second-ranked Abbott Diabetes Care at 28. Together, the top five applicants hold 72% of the hundred largest filers’ combined total.
The field is classified as Growth. Recent three-year filings sit 28% above the prior three-year window. Annual volume peaked in 2022 at 32 records and has since eased, but the most recent years (2024–2026) are materially undercounted due to publication lag and should not be read as a decline.
The United States leads with 109 patent records, followed by Europe (EPO) at 38, Australia at 24, and WIPO (PCT) at 23. Canada carries 19 records. China and India each have only 5 records, indicating limited defensive filing in those markets to date.
Collaboration is sparse. The most active co-filing pair is Abbott Diabetes Care and Cambridge Enterprise, which have co-filed on 4 patent records. Dexcom and the University of Padova share 1 co-filed record. The low collaboration density indicates the field is prosecuted mainly through internal R&D pipelines.
The sparsest adjacent branches relative to their technical relevance are AI-model computing (G06N, 11 records, 2% share) and display control circuits (G09G, 17 records, 3% share). Both are thinly claimed despite direct applicability to predictive alerting and wearable display optimization. Wireless communication networks (H04W, 24 records) and digital information transmission (H04L, 10 records) are also under-served.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.